On February 12, 2024, Tonix Pharmaceuticals received clearance from the FDA for its Investigational New Drug (IND) application regarding the Phase 2 OASIS trial for TNX-102 SL. This trial aims to alleviate the severity of acute stress reactions and decrease the frequency of acute stress disorder and posttraumatic stress disorder.
Sponsored by The University of North Carolina (UNC) Institute for Trauma Recovery and supported by a generous $3 million grant from the U.S. Department of Defense (DoD), the OASIS trial is set to pave the way for potential breakthroughs in the treatment of these conditions.
With the IND clearance in place, the trial can now move forward, marking a significant milestone in the development of TNX-102 SL as a promising therapeutic option for individuals affected by acute trauma. This groundbreaking clinical trial and collaborative partnership will undoubtedly contribute to addressing the pressing need for safe and effective therapies in this field.
TNXP Stock Shows Promising Signs with Potential Growth Opportunities for Investors on February 12, 2024
On February 12, 2024, TNXP stock showed promising signs as it traded near the bottom of its 52-week range and below its 200-day simple moving average, indicating potential growth opportunities for investors. Starting the day at $0.33, TNXP shares experienced a slight increase of $0.02 in pre-market trading, further solidifying the positive sentiment surrounding the stock. This 0.03% rise in price since the market last closed indicated a potential upward trend for the day. Trading near the bottom of its 52-week range, TNXP stock presented an opportunity for investors to enter at a relatively low price point. Additionally, trading below its 200-day simple moving average could be seen as a potential buying signal for technical traders. It is important to note that the price change of TNXP shares since the market last closed was $0.00, indicating a relatively stable performance. However, the pre-market trading activity showed a positive increase of $0.02, suggesting that the stock had the potential to continue its upward trajectory throughout the day. Investors should closely monitor TNXP’s performance throughout the trading session to assess whether the positive momentum continues. As with any investment, it is crucial to conduct thorough research and consider various factors before making any trading decisions. Consulting with a financial advisor or conducting independent analysis can further assist investors in making informed choices. In conclusion, TNXP stock’s performance on February 12, 2024, showed promising signs with its trading near the bottom of its 52-week range and below its 200-day simple moving average. The slight increase in pre-market trading indicated a potential upward trend for the day. Investors should closely monitor the stock’s performance throughout the trading session to assess its continued momentum.
TNXP Stock Performance on February 12, 2024: Mixed Results and Notable Improvements in EPS
On February 12, 2024, TNXP stock exhibited mixed performances based on the available data from CNN Money. TNXP reported a net income of -$110.22 million for the past year, which represents a decrease of 19.43% compared to the previous year. In the third quarter, TNXP’s net income improved to -$27.98 million, reflecting a 1.34% increase compared to the previous quarter. The earnings per share (EPS) for the past year was -$20.44, indicating a significant loss per share. However, there has been a notable improvement in EPS, with a 60.11% increase compared to the previous year. In the third quarter, the EPS improved further to -$1.83, representing a 31.86% increase compared to the previous quarter. Overall, TNXP’s stock performance on February 12, 2024, shows mixed results.
